How does a mid-sized biotech company break through in the competitive world of medical aesthetics and implants?

In 2021, Maxigen Biotech welcomed new leadership with the appointment of Cindy Chen as CEO at just 36 years old—making her one of the youngest executives to lead a publicly traded biotech firm in Taiwan.

With a background in laboratory research and hands-on industry experience, Chen transitioned from bench to boardroom, now overseeing a team of over 100 employees. Her leadership is defined by a dual focus on scientific rigor and market-driven innovation, steering Maxigen Biotech through a new chapter of accelerated growth.

Led by CEO Cindy Chen, Maxigen Biotech has built a portfolio of 116 international regulatory approvals across orthopedics, dentistry, ophthalmology, aesthetics, and surgery. The secret? A strong R&D engine (16% of revenue reinvested), a deep commitment to biopolymer science—especially in hyaluronic acid and collagen—and bold international expansion.

From extracting native collagen from bovine tendons to minimizing BDDE in HA cross-linking for higher safety and efficacy, Maxigen Biotech is turning technical edge into market value. Their in-house product lines span injectable HA for osteoarthritis and aesthetics, as well as innovative collagen dressings and dietary supplements co-developed with strategic partners.

As Taiwan’s biotech ecosystem matures, Maxigen Biotech exemplifies how technical depth, regulatory ambition, and cross-sector collaboration can fuel sustainable growth.

Learn how strategic leadership shapes product innovation →

Read more: http://bit.ly/v107spreport

Follow Globalbio for more updates on Medtech!